# Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

> **NCT05275205** · PHASE2 · COMPLETED · sponsor: **Unity Biotechnology, Inc.** · enrollment: 51 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** UBX1325 injection 50 μL
- **DRUG:** EYLEA® (aflibercept) Injection 2 mg (0.05mL)

## Key facts

- **NCT ID:** NCT05275205
- **Lead sponsor:** Unity Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-02
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-07-25
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275205, "Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05275205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*